LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 45

Search options

  1. Article ; Online: Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells

    Jansen, Jade / Kroeze, Stefanie / Man, Shirley / Andreini, Matteo / Bakker, Jan-Willem / Zamperini, Claudio / Tarditi, Alessia / Kootstra, Neeltje A / Geijtenbeek, Teunis B H

    Microbiology spectrum

    2023  Volume 12, Issue 1, Page(s) e0318023

    Abstract: Importance: HIV-1 continues to be a major global health challenge. Current HIV-1 treatments are effective but need lifelong adherence. An HIV-1 cure should eliminate the latent viral reservoir that persists in people living with HIV-1. Different methods ...

    Abstract Importance: HIV-1 continues to be a major global health challenge. Current HIV-1 treatments are effective but need lifelong adherence. An HIV-1 cure should eliminate the latent viral reservoir that persists in people living with HIV-1. Different methods have been investigated that focus on reactivation and subsequent elimination of the HIV-1 reservoir, and it is becoming clear that a combination of compounds with different mechanisms of actions might be more effective. Here, we target two host factors, inhibitor of apoptosis proteins that control apoptosis and the DEAD-box helicase DDX3, facilitating HIV mRNA transport/translation. We show that targeting of these host factors with SMAC mimetics and DDX3 inhibitors induce reversal of viral latency and eliminate HIV-1-infected cells
    MeSH term(s) Humans ; HIV-1 ; NF-kappa B/metabolism ; HIV Infections/drug therapy ; HIV Infections/genetics ; CD4-Positive T-Lymphocytes ; Gene Expression Regulation ; Virus Latency
    Chemical Substances NF-kappa B
    Language English
    Publishing date 2023-12-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2807133-5
    ISSN 2165-0497 ; 2165-0497
    ISSN (online) 2165-0497
    ISSN 2165-0497
    DOI 10.1128/spectrum.03180-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs.

    Borgini, Matteo / Zamperini, Claudio / Poggialini, Federica / Ferrante, Luca / Summa, Vincenzo / Botta, Maurizio / Fabio, Romano Di

    ACS medicinal chemistry letters

    2020  Volume 11, Issue 5, Page(s) 846–851

    Abstract: The marine natural product Largazole is the most potent Class I HDAC inhibitor identified to date. Since its discovery, many research groups have been attracted by the structural complexity and the peculiar anticancer activity, due to its capability to ... ...

    Abstract The marine natural product Largazole is the most potent Class I HDAC inhibitor identified to date. Since its discovery, many research groups have been attracted by the structural complexity and the peculiar anticancer activity, due to its capability to discriminate between tumor cells and normal cells. Herein, we discuss the synthesis and the
    Language English
    Publishing date 2020-02-07
    Publishing country United States
    Document type Journal Article
    ISSN 1948-5875
    ISSN 1948-5875
    DOI 10.1021/acsmedchemlett.9b00643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The Pyrazolo[3,4-

    Rango, Enrico / Pastorino, Fabio / Brignole, Chiara / Mancini, Arianna / Poggialini, Federica / Di Maria, Salvatore / Zamperini, Claudio / Iovenitti, Giulia / Fallacara, Anna Lucia / Sabetta, Samantha / Clementi, Letizia / Valoti, Massimo / Schenone, Silvia / Angelucci, Adriano / Ponzoni, Mirco / Dreassi, Elena / Botta, Maurizio

    Biomedicines

    2022  Volume 10, Issue 3

    Abstract: Si306, a pyrazolo[3,4- ...

    Abstract Si306, a pyrazolo[3,4-
    Language English
    Publishing date 2022-03-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines10030659
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.

    Rango, Enrico / D'Antona, Lucia / Iovenitti, Giulia / Brai, Annalaura / Mancini, Arianna / Zamperini, Claudio / Trivisani, Claudia Immacolata / Marianelli, Stefano / Fallacara, Anna Lucia / Molinari, Alessio / Cianciusi, Annarita / Schenone, Silvia / Perrotti, Nicola / Dreassi, Elena / Botta, Maurizio

    European journal of medicinal chemistry

    2021  Volume 223, Page(s) 113653

    Abstract: Si113, a pyrazolo[3,4-d]pyrimidine derivative, gained more attention as an anticancer agent due to its potent anticancer activity on both in vitro and in vivo hepatocellular carcinomas (HCC) and ovarian carcinoma models. But the drawback is the low water ...

    Abstract Si113, a pyrazolo[3,4-d]pyrimidine derivative, gained more attention as an anticancer agent due to its potent anticancer activity on both in vitro and in vivo hepatocellular carcinomas (HCC) and ovarian carcinoma models. But the drawback is the low water solubility which prevents its further development. In this context, we successfully overcame this limitation by synthesizing two novel prodrugs introducing the amino acid sequence D-Ala-Leu-Lys (TP). Moreover, TP sequence has a high affinity with plasmin, a protease recognized as overexpressed in many solid cancers, including HCC and ovarian carcinoma. The prodrugs were synthesized and fully characterized in terms of in vitro ADME properties, plasma stability and plasmin-induced release of the parent drug. The inhibitory activity against Sgk1 was evaluated and in vitro growth inhibition was evaluated on ovarian carcinoma and HCC cell lines in the presence and absence of human plasmin. In vivo pharmacokinetic properties and preliminary tissue distribution confirmed a better profile highlighting the importance of the prodrug approach. Finally, the prodrug antitumor efficacy was evaluated in an HCC xenografted murine model, where a significant reduction (around 90%) in tumor growth was observed. Treatment with ProSi113-TP in combination with paclitaxel in a paclitaxel-resistant ovarian carcinoma xenografted murine model, resulted in an impressive reduction of tumor volume greater than 95%. Our results revealed a promising activity of Si113 prodrugs and pave the way for their further development against resistant cancer.
    MeSH term(s) Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/metabolism ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/drug effects ; Drug Stability ; Female ; Fibrinolysin/metabolism ; Half-Life ; Humans ; Immediate-Early Proteins/antagonists & inhibitors ; Immediate-Early Proteins/metabolism ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Mice ; Mice, Nude ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Prodrugs/chemistry ; Prodrugs/metabolism ; Prodrugs/pharmacology ; Prodrugs/therapeutic use ; Protein-Serine-Threonine Kinases/antagonists & inhibitors ; Protein-Serine-Threonine Kinases/metabolism ; Pyrazoles/chemistry ; Pyrazoles/metabolism ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Pyrimidines/chemistry ; Pyrimidines/metabolism ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Transplantation, Heterologous
    Chemical Substances Antineoplastic Agents ; Immediate-Early Proteins ; Prodrugs ; Pyrazoles ; Pyrimidines ; pyrazolo(3,4-d)pyrimidine (271-80-7) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1) ; serum-glucocorticoid regulated kinase (EC 2.7.11.1) ; Fibrinolysin (EC 3.4.21.7) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2021-06-17
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2021.113653
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-

    Calandro, Pierpaolo / Iovenitti, Giulia / Zamperini, Claudio / Candita, Francesca / Dreassi, Elena / Chiariello, Mario / Angelucci, Adriano / Schenone, Silvia / Botta, Maurizio / Mancini, Arianna

    ACS medicinal chemistry letters

    2018  Volume 9, Issue 7, Page(s) 646–651

    Abstract: Hepatocellular carcinoma (HCC) is one of the most fatal cancer types worldwide. HCC cells were proved to overexpress c-Src and Sgk1, a tyrosine and a serine-threonine kinase, respectively, whose role is crucial for the development and progression of the ... ...

    Abstract Hepatocellular carcinoma (HCC) is one of the most fatal cancer types worldwide. HCC cells were proved to overexpress c-Src and Sgk1, a tyrosine and a serine-threonine kinase, respectively, whose role is crucial for the development and progression of the tumor. Pyrazolo[3,4-
    Language English
    Publishing date 2018-05-07
    Publishing country United States
    Document type Journal Article
    ISSN 1948-5875
    ISSN 1948-5875
    DOI 10.1021/acsmedchemlett.8b00062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X.

    Brai, Annalaura / Ronzini, Stefania / Riva, Valentina / Botta, Lorenzo / Zamperini, Claudio / Borgini, Matteo / Trivisani, Claudia Immacolata / Garbelli, Anna / Pennisi, Carla / Boccuto, Adele / Saladini, Francesco / Zazzi, Maurizio / Maga, Giovanni / Botta, Maurizio

    Molecules (Basel, Switzerland)

    2019  Volume 24, Issue 21

    Abstract: The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its ... ...

    Abstract The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its inhibitory action on the ATPase activity of the enzyme. The potential use of the most promising derivatives it has been investigated by evaluating their anti-HIV-1 effects, revealing inhibitory activities in the low micromolar range. A preliminary ADME analysis demonstrated high metabolic stability and good aqueous solubility. The promising biological profile, together with the suitable in vitro pharmacokinetic properties, make these novel compounds a very good starting point for further development.
    MeSH term(s) Antiviral Agents/chemical synthesis ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; DEAD-box RNA Helicases/antagonists & inhibitors ; HIV-1/drug effects ; Humans ; Thiadiazoles/chemistry ; Virus Replication/drug effects
    Chemical Substances Antiviral Agents ; Thiadiazoles ; 1,3,4-thiadiazole (14IAC3GH7G) ; DDX3X protein, human (EC 3.6.1.-) ; DEAD-box RNA Helicases (EC 3.6.4.13)
    Language English
    Publishing date 2019-11-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules24213988
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.

    Brai, Annalaura / Martelli, Francesco / Riva, Valentina / Garbelli, Anna / Fazi, Roberta / Zamperini, Claudio / Pollutri, Alessandro / Falsitta, Lucia / Ronzini, Stefania / Maccari, Laura / Maga, Giovanni / Giannecchini, Simone / Botta, Maurizio

    Journal of medicinal chemistry

    2019  Volume 62, Issue 5, Page(s) 2333–2347

    Abstract: Increased frequency of arbovirus outbreaks in the last 10 years represents an important emergence for global health. Climate warming, extensive urbanization of tropical regions, and human migration flows facilitate the expansion of anthropophilic ... ...

    Abstract Increased frequency of arbovirus outbreaks in the last 10 years represents an important emergence for global health. Climate warming, extensive urbanization of tropical regions, and human migration flows facilitate the expansion of anthropophilic mosquitos and the emerging or re-emerging of new viral infections. Only recently the human adenosinetriphosphatase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against infectious diseases. Herein, starting from our previous studies, a new family of DDX3X inhibitors was designed, synthesized, validated on the target enzyme, and evaluated against the West Nile virus (WNV) infection. Time of addition experiments after virus infection indicated that the compounds exerted their antiviral activities after the entry process, likely at the protein translation step of WNV replication. Finally, the most interesting compounds were then analyzed for their in vitro pharmacokinetic parameters, revealing favorable absorption, distribution, metabolism, and excretion values. The good safety profile together with a good activity against WNV for which no treatments are currently available, make this new class of molecules a good starting point for further in vivo studies.
    MeSH term(s) A549 Cells ; Animals ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Chlorocebus aethiops ; DEAD-box RNA Helicases/antagonists & inhibitors ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Humans ; Vero Cells ; Virus Replication/drug effects ; West Nile Fever/drug therapy ; West Nile virus/drug effects ; West Nile virus/enzymology ; West Nile virus/physiology
    Chemical Substances Antiviral Agents ; Enzyme Inhibitors ; DDX3X protein, human (EC 3.6.1.-) ; DEAD-box RNA Helicases (EC 3.6.4.13)
    Language English
    Publishing date 2019-02-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.8b01403
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins.

    Brai, Annalaura / Riva, Valentina / Saladini, Francesco / Zamperini, Claudio / Trivisani, Claudia Immacolata / Garbelli, Anna / Pennisi, Carla / Giannini, Alessia / Boccuto, Adele / Bugli, Francesca / Martini, Maurizio / Sanguinetti, Maurizio / Zazzi, Maurizio / Dreassi, Elena / Botta, Maurizio / Maga, Giovanni

    European journal of medicinal chemistry

    2020  Volume 200, Page(s) 112319

    Abstract: The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people ... ...

    Abstract The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people living with HIV. However, life-long treatments could result in the emergence of drug-resistant viruses that can progressively reduce the number of therapeutic options, facilitating the progression of the disease. In this scenario, we previously demonstrated that inhibitors of the human DDX3X helicase can represent an innovative approach for the simultaneous treatment of HIV and other viral infections such as Hepatitis c virus (HCV). We reported herein 6b, a novel DDX3X inhibitor that thanks to its distinct target of action is effective against HIV-1 strains resistant to currently approved drugs. Its improved in vitro ADME properties allowed us to perform preliminary in vivo studies in mice, which highlighted optimal biocompatibility and an improved bioavailability. These results represent a significant advancement in the development of DDX3X inhibitors as a novel class of broad spectrum and safe anti-HIV-1 drugs.
    MeSH term(s) Animals ; Anti-HIV Agents/chemistry ; Anti-HIV Agents/pharmacology ; DEAD-box RNA Helicases/antagonists & inhibitors ; Drug Resistance, Viral/drug effects ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; HIV-1/physiology ; Humans ; Mice ; Virus Diseases/drug therapy
    Chemical Substances Anti-HIV Agents ; Enzyme Inhibitors ; DDX3X protein, human (EC 3.6.1.-) ; DEAD-box RNA Helicases (EC 3.6.4.13)
    Language English
    Publishing date 2020-05-07
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2020.112319
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51.

    De Vita, Daniela / Moraca, Francesca / Zamperini, Claudio / Pandolfi, Fabiana / Di Santo, Roberto / Matheeussen, An / Maes, Louis / Tortorella, Silvano / Scipione, Luigi

    European journal of medicinal chemistry

    2016  Volume 113, Page(s) 28–33

    Abstract: Sterol 14α-demethylase (CYP51) is a key enzyme involved in the survival and virulence of many parasite protozoa, such as Trypanosoma and Leishmania species, thus representing a valuable drug target for the treatment of Kinetoplastid diseases. A set of ... ...

    Abstract Sterol 14α-demethylase (CYP51) is a key enzyme involved in the survival and virulence of many parasite protozoa, such as Trypanosoma and Leishmania species, thus representing a valuable drug target for the treatment of Kinetoplastid diseases. A set of azole-based compounds selected from an in-house compound library was in vitro screened against different human protozoan parasites. Several compounds showed selective activity against Trypanosoma cruzi, with compound 7 being the most active (IC50 = 40 nM). Given the structural similarity between the compounds here reported and known CYP51 inhibitors, a molecular docking study was performed to assess their binding with protozoal target and to rationalize the biological activity data.
    MeSH term(s) Antiprotozoal Agents/chemical synthesis ; Antiprotozoal Agents/chemistry ; Antiprotozoal Agents/pharmacology ; Cell Line ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Fibroblasts/drug effects ; Humans ; Imidazoles/chemical synthesis ; Imidazoles/chemistry ; Imidazoles/pharmacology ; Molecular Docking Simulation ; Molecular Structure ; Parasitic Sensitivity Tests ; Phenylethyl Alcohol/analogs & derivatives ; Phenylethyl Alcohol/chemical synthesis ; Phenylethyl Alcohol/chemistry ; Phenylethyl Alcohol/pharmacology ; Structure-Activity Relationship ; Trypanosoma cruzi/drug effects
    Chemical Substances 2-(1H-imidazol-1-yl)-1-phenylethanol ; Antiprotozoal Agents ; Imidazoles ; Phenylethyl Alcohol (ML9LGA7468)
    Language English
    Publishing date 2016-05-04
    Publishing country France
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2016.02.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models.

    Brai, Annalaura / Riva, Valentina / Clementi, Letizia / Falsitta, Lucia / Zamperini, Claudio / Sinigiani, Virginia / Festuccia, Claudio / Sabetta, Samantha / Aiello, Davide / Roselli, Camilla / Garbelli, Anna / Trivisani, Claudia Immacolata / Maccari, Laura / Bugli, Francesca / Sanguinetti, Maurizio / Calandro, Pierpaolo / Chiariello, Mario / Quaranta, Paola / Botta, Lorenzo /
    Angelucci, Adriano / Maga, Giovanni / Botta, Maurizio

    Cancers

    2021  Volume 13, Issue 21

    Abstract: DDX3X is an ATP-dependent RNA helicase that has recently attracted interest for its involvement in viral replication and oncogenic progression. Starting from hit compounds previously identified by our group, we have designed and synthesized a new series ... ...

    Abstract DDX3X is an ATP-dependent RNA helicase that has recently attracted interest for its involvement in viral replication and oncogenic progression. Starting from hit compounds previously identified by our group, we have designed and synthesized a new series of DDX3X inhibitors that effectively blocked its helicase activity. These new compounds were able to inhibit the proliferation of cell lines from different cancer types, also in DDX3X low-expressing cancer cell lines. According to the absorption, distribution, metabolism, elimination properties, and antitumoral activity, compound BA103 was chosen to be further investigated in glioblastoma models. BA103 determined a significant reduction in the proliferation and migration of U87 and U251 cells, downregulating the oncogenic protein β-catenin. An in vivo evaluation demonstrated that BA103 was able to reach the brain and reduce the tumor growth in xenograft and orthotopic models without evident side effects. This study represents the first demonstration that DDX3X-targeted small molecules are feasible and promising drugs also in glioblastoma.
    Language English
    Publishing date 2021-11-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13215569
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top